HIGHLIGHTS
- who: Henning Hvid from the v, Denmark have published the research: Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models, in the Journal: (JOURNAL)
- what: The aim of this study was therefore to engineer a dual-acting molecule with combined GCGR antagonistic effect and liver-preferential insulin action and explore its pharmacological effects.
- how: In vivo data were analysed using general linear models followed by pairwise comparison of treatment groups with Tukey`s adjustment for multiple parallel pairwise comparisons . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.